Imfinzi sBLA for Nonsmall-Cell Lung Cancer Hits Snag in AdComm

A supplemental BLA for AstraZeneca’s blockbuster cancer drug Imfinzi (durvalumab) for treatment of nonsmall-cell lung cancer (NSCLC) hit a potential speed bump Thursday in a review by the FDA’s oncology advisory panel of the supporting clinical trial.
Source: Drug Industry Daily